SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently drawing significant attention as investors react to its relative strength against Bitcoin and key institutional inflows ahead of upcoming CPI data. The community remains deeply divided, with bulls pointing to historical April performance and potential breakout catalysts, while skeptics warn of persistent market volatility and macroeconomic pressures affecting crypto valuations.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently trading in a highly volatile spotlight following a public endorsement from President Trump, which has ignited intense debate between bulls citing the company's critical role in national security and bears echoing Michael Burry's skepticism regarding its valuation and competitive threats. The community remains sharply divided, with active discussion focused on whether the stock is primed for a major short squeeze driven by institutional accumulation or if it faces further downside as it navigates a challenging sector-wide software sell-off.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is at the center of a heated debate between retail traders betting on a leveraged Bitcoin recovery and skeptics warning of significant share dilution and potential downward pressure. While bulls point to aggressive institutional accumulation and the stock's role as a high-beta proxy for Bitcoin, bears remain focused on the company's continuous capital raises and its tendency to lag during crypto market swings.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging as investors closely monitor topline results from its Phase 2/3 OptimUM-02 trial evaluating darovasertib in metastatic uveal melanoma. The community is actively debating the potential for an accelerated approval filing and questioning the significance of the partnership with Servier ahead of this high-stakes data release.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is seeing massive momentum driven by a recent integration with World Liberty Financial and expanding interest in its unique Web3 music and live event ecosystem. While the community is actively debating its parabolic rise and long-term potential for utility-based growth, many are also expressing caution regarding potential volatility and the risks inherent in such a rapid, hype-driven price surge.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is experiencing significant volatility driven by the U.S. government's announcement of a naval blockade in the Strait of Hormuz following the collapse of diplomatic talks with Iran. The community is sharply divided, with bulls betting on a quick market recovery despite geopolitical tensions, while bears point to the blockade as a major escalation that threatens global energy supply chains and complicates the broader macro outlook.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as the community anticipates major near-term catalysts, including upcoming Phase 3 trial completions and pancreatic cancer data presentations at the Digestive Disease Week conference. Investor sentiment remains heavily bullish, driven by the companys strong cash position, recent analyst price target upgrades, and the high-conviction belief that its proprietary alpha-radiation technology is significantly undervalued.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as investors rally behind a new multi-billion dollar strategic partnership with Nvidia that integrates their respective AI infrastructure and custom chip ecosystems. The community is actively discussing the stock's breakout potential as it reclaims key resistance levels, with many traders focusing on the company's surging optics business and long-term positioning within the AI supply chain.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing heavy retail and institutional interest as investors bet on the company's electro-optic polymer technology as a scalable solution for AI data centers. The community is actively debating the transition from R&D to foundry-integrated manufacturing, with recent partnerships and expectations of upcoming tape-out results driving volatility and ongoing speculation about potential major industry acquisitions.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and community members react to reports of a planned U.S. naval blockade in the Strait of Hormuz, fueling intense debate over global energy security and potential market volatility. Discussions are heavily polarized, with supporters praising the administration's aggressive geopolitical stance while critics express significant concern over the economic impact, diplomatic fallout, and the stability of the current presidential term.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fate Therapeutics (NASDAQ:FATE) Share Price Passes Below 200-Day Moving Average - Here's What Happened

Fate Therapeutics (NASDAQ:FATE) Stock Passes Below Two Hundred Day Moving Average - Should You Sell...

Scalable Biotech Manufacturing Unlocks a $14B Market

Scalable Biotech Manufacturing Unlocks a $14B Market Scalable Biotech Manufacturing Unlocks a $14B Market PR Newswire VANCOUVER, BC, March 27, 2026 Issued on behalf of Ava Bio, Inc.VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary The global cell therapy manufacturing...

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages

Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has earned an average rating of "Hold" from the eight ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and three have...

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 14.1% in February

Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) was the recipient of a large drop in short interest in the month of February. As of February 27th, there was short interest totaling 9,563,527...

Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference

Fate Therapeutics (NASDAQ:FATE) CEO Bob Valamehr outlined the company's clinical and manufacturing strategy for FT819, an off-the-shelf allogeneic CAR T-cell therapy, during a conference fireside...

Fate Therapeutics (NASDAQ:FATE) Posts Earnings Results, Meets Expectations

Fate Therapeutics (NASDAQ:FATE - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, meeting analysts...

Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of +1.21% and -8.73%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Summary: Fate Therapeutics Q4

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts

Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has been given a consensus recommendation of "Hold" by the nine research firms that are presently covering the stock, MarketBeat Ratings...

Fate Therapeutics (FATE) to Release Earnings on Wednesday

Fate Therapeutics (NASDAQ:FATE) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 4. (View Earnings Report at...

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Current Price	$1.24
Prev Close	$1.27
Open	$1.28
Dividend Yield	0.00%
50-Day Moving Average	$1.25
Beta	1.67
Avg. Volume	1.47M
PE Ratio	-1.08

52-Week High	$1.94
52-Week Low	$0.8651
Market Capitalization	$144.17M
EPS (Annual)	-$1.15
Price to Book	0.69
Revenue Per Employee	$41,279.50

FATE
Fate Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FATE News

FATEFate Therapeutics Inc